Injectable Semaglutide has not been evaluated by the FDA, but side effects are expected to be similar to other Semaglutide-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)
[iii] Oral Astaxanthin Supplements (2mg for 12 weeks) Reduced Water Loss and Increased Skin Elasticity in 44 Healthy Female Adults [iv] Izumi et al., 2009
The enforcement scale is real: more than 455 FDA adverse-event reports tied to compounded semaglutide, over 50 warning letters to compounded GLP-1 sellers in 2025, and 30-plus more in March 2026, several of them naming the compounding pharmacies behind telehealth brands
The rate of gastric emptying is also of clinical importance in the context of advanced bolus programs in insulin pumps